ClinicalTrialsFinder
RecruitingNCT06786663

MALE Mamm Organoids

Feasibility Study for the Generation of Organoids From Male Breast Tumors

Sponsor

Regina Elena Cancer Institute

Enrollment

7 participants

Start Date

Apr 19, 2024

Study Type

OBSERVATIONAL

Conditions

Breast Neoplasms, Male

Summary

It is believed that the use of organoids derived from male breast tumors can be of fundamental support for the definition of the molecular mechanisms underlying the onset of the tumor. Furthermore, the development of such preclinical models could be of significant support for the identification of specific personalized and ad hoc therapeutic treatments for male pathology.

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting tissue samples from men with breast cancer to create laboratory models called organoids — tiny tumor replicas grown in a lab — so researchers can study male breast cancer (which is rare and understudied) and develop better treatments. **You may be eligible if...** - You are a man over 18 years old - You have been diagnosed with breast cancer (with or without spread to other organs) confirmed by tissue biopsy - You are scheduled for surgery related to your breast cancer - Enough tissue sample can be collected for analysis - You have signed informed consent **You may NOT be eligible if...** - No specific exclusion criteria are listed for this study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

IRCCS National Cancer Institute "Regina Elena"

Rome, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06786663

Related Trials

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

NCT0680581224 locations